DE69434428T2 - Neue Polypeptide und diese codierende DNAs - Google Patents

Neue Polypeptide und diese codierende DNAs Download PDF

Info

Publication number
DE69434428T2
DE69434428T2 DE69434428T DE69434428T DE69434428T2 DE 69434428 T2 DE69434428 T2 DE 69434428T2 DE 69434428 T DE69434428 T DE 69434428T DE 69434428 T DE69434428 T DE 69434428T DE 69434428 T2 DE69434428 T2 DE 69434428T2
Authority
DE
Germany
Prior art keywords
dna
seq
polypeptide
cdna
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434428T
Other languages
German (de)
English (en)
Other versions
DE69434428D1 (de
Inventor
Tasuku Sakyo-ku Honjo
Michio Kyoto-shi Shirozu
Hideaki Shimamotocho Tada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Publication of DE69434428D1 publication Critical patent/DE69434428D1/de
Application granted granted Critical
Publication of DE69434428T2 publication Critical patent/DE69434428T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
DE69434428T 1993-10-14 1994-10-13 Neue Polypeptide und diese codierende DNAs Expired - Lifetime DE69434428T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP28050593 1993-10-14
JP28050593 1993-10-14

Publications (2)

Publication Number Publication Date
DE69434428D1 DE69434428D1 (de) 2005-08-25
DE69434428T2 true DE69434428T2 (de) 2006-05-24

Family

ID=17626033

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69434428T Expired - Lifetime DE69434428T2 (de) 1993-10-14 1994-10-13 Neue Polypeptide und diese codierende DNAs

Country Status (12)

Country Link
US (2) US5563048A (enExample)
EP (2) EP0657468B1 (enExample)
JP (4) JP3367581B2 (enExample)
KR (1) KR100210308B1 (enExample)
CN (1) CN1062908C (enExample)
AT (1) ATE299891T1 (enExample)
CA (1) CA2117953C (enExample)
DE (1) DE69434428T2 (enExample)
DK (1) DK0657468T3 (enExample)
ES (1) ES2244955T3 (enExample)
PT (1) PT657468E (enExample)
TW (1) TW302369B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751658B1 (fr) * 1996-07-26 1998-10-02 Pasteur Institut Utilisation d'une chemokine (sdf-1) ligand pour le recepteur de lestr/fusin/cxcr4 pour prevenir ou traiter l'infection par des virus de type vih
EP1012275A1 (en) * 1997-01-31 2000-06-28 University Of Rochester Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
US6852508B1 (en) * 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US6100387A (en) * 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
DE19734161A1 (de) * 1997-08-07 1999-04-01 Jerini Biotools Gmbh SDF-1 - Antagonisten
MXPA00003885A (es) * 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
CA2245224A1 (en) * 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
DE69914463T2 (de) * 1998-03-13 2004-11-11 The University Of British Columbia, Vancouver Therapeutische chemokine rezeptor antagonisten
DE69932510T2 (de) * 1998-03-24 2007-02-15 Chugai Seiyaku K.K. Vaskularisierungsinhibitoren
EP2308996A1 (en) 1998-03-30 2011-04-13 NorthWest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 and SDF-1 genes in tumourigenesis
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
AU5241099A (en) * 1998-07-31 2000-02-21 Trustees Of Columbia University In The City Of New York, The Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
WO2000059941A1 (en) * 1999-04-08 2000-10-12 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
US6949243B1 (en) * 1999-11-24 2005-09-27 Schering Corporation Methods of inhibiting metastasis
US7378098B2 (en) * 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US7368425B2 (en) * 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
CA2335109A1 (en) * 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
US20050059584A1 (en) * 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
DE10027383A1 (de) * 2000-06-02 2001-12-20 Rhein Biotech Proz & Prod Gmbh Nukleinsäure-Molekül umfassend eine für ein Chemokin, einen Neuropeptid-Präkursor oder mindestens ein Neuropeptid kodierende Nukleinsäuresequenz
US20020094327A1 (en) * 2000-11-05 2002-07-18 Petersen Bryon E. Targeting pluripotent stem cells to tissues
JP2004155010A (ja) 2002-11-06 2004-06-03 Sony Corp 可逆性多色記録媒体、及びこれを用いた記録方法
JP2004074583A (ja) 2002-08-19 2004-03-11 Sony Corp 可逆性多色記録媒体、及びこれを用いた記録方法
WO2006032143A1 (en) * 2004-09-23 2006-03-30 Arc Pharmaceuticals, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
CN101103101B (zh) * 2004-09-24 2012-10-10 成血管细胞系统公司 增强间充质前体细胞（mpc）的增生和/或存活的方法
JP2008519052A (ja) * 2004-11-05 2008-06-05 ザ ジェネラル ホスピタル コーポレイション 薬剤によるヒト遊走性細胞の合目的的挙動
US20060264365A1 (en) * 2005-05-18 2006-11-23 Hung Li Treatment of brain tissue damage
WO2007048846A1 (de) * 2005-10-27 2007-05-03 Neuraxo Biopharmaceuticals Gmbh Verwendung von eisen chelatisierenden verbindungen, zyklisches adenosinmonophosphat erhöhende verbindungen oder kombinationen davon zur behandlung von axonalen läsionen im zns
WO2007051785A2 (en) * 2005-10-31 2007-05-10 Laboratoire Serono S.A. Use of sdf-1 for the treatment and/or prevention of neurological diseases
CN100432106C (zh) * 2006-06-02 2008-11-12 广东省微生物研究所 一种附着法保藏抗菌肽的方法
US20090291887A1 (en) * 2006-07-07 2009-11-26 Mueller Hans-Werner Proteins of the SDF-1-Family for the Manufacturing of a Medicament
SI2066351T1 (sl) 2006-10-02 2016-02-29 E.R. Squibb & Sons, L.L.C. Humana protitelesa, ki vežejo cxcr4 in njihova uporaba
US7696309B2 (en) * 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US20110044945A1 (en) * 2007-02-08 2011-02-24 Rappaport Family Institute For Research In The Medical Sciences Agents for the treatment of multiple sclerosis and methods of using same
KR100767841B1 (ko) 2007-03-30 2007-10-18 주식회사 욱성 3중층 구조의 경편직물로 구성한 타이어체인
WO2008149354A2 (en) 2007-06-04 2008-12-11 Rappaport Family Institute For Research In The Medical Sciences Agents for the treatment of inflammatory diseases and methods of using same
AU2008336249B2 (en) 2007-12-10 2015-01-29 The University Of Queensland Treatment and prophylaxis
CN101229184B (zh) * 2008-01-17 2010-08-11 周锡漳 一种脱氧核糖核酸降解片段复合物及其制备药物的应用
WO2011106234A1 (en) 2010-02-25 2011-09-01 Provasculon, Inc. Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US20130252876A1 (en) * 2010-09-15 2013-09-26 The Cleveland Clinic Foundation Compositions and method for promoting musculoskeletal repair
JP6145089B2 (ja) 2011-06-07 2017-06-07 メソブラスト インターナショナル エスエイアールエル ストロマ細胞由来因子−１のプロテアーゼ耐性変異体を用いた、組織損傷を修復するための方法
HUE043001T2 (hu) 2011-11-09 2019-07-29 Bristol Myers Squibb Co Hematológiai malignómák kezelése anti-CXCR4 antitesttel
US9908923B2 (en) 2014-06-11 2018-03-06 The Medical College Of Wisconsin, Inc. Monomeric CXCL121 peptide and methods of use thereof
DK3050574T3 (da) 2015-01-28 2020-01-20 Univ Bordeaux Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
WO2016191811A1 (en) 2015-06-03 2016-12-08 The University Of Queensland Mobilizing agents and uses therefor
EP3692139B1 (en) 2017-10-03 2024-11-06 SDF BioPharma Inc. Treating diabetes with genetically modified beta cells
KR102381876B1 (ko) * 2021-10-27 2022-04-01 홍천석 전선터미널 압착시스템

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2879303B2 (ja) * 1993-01-14 1999-04-05 佑 本庶 ｃＤＮＡライブラリーの作製方法、および新規なポリペプチドとそれをコードするＤＮＡ

Also Published As

Publication number Publication date
ATE299891T1 (de) 2005-08-15
DE69434428D1 (de) 2005-08-25
KR100210308B1 (ko) 1999-07-15
CA2117953C (en) 2001-12-11
US5563048A (en) 1996-10-08
DK0657468T3 (da) 2005-08-08
CN1110323A (zh) 1995-10-18
JP3705732B2 (ja) 2005-10-12
EP1557428A1 (en) 2005-07-27
CA2117953A1 (en) 1995-04-15
JP2005336198A (ja) 2005-12-08
US5756084A (en) 1998-05-26
JP3367581B2 (ja) 2003-01-14
EP0657468A1 (en) 1995-06-14
EP0657468B1 (en) 2005-07-20
JPH07188294A (ja) 1995-07-25
PT657468E (pt) 2005-10-31
JP2007291132A (ja) 2007-11-08
ES2244955T3 (es) 2005-12-16
CN1062908C (zh) 2001-03-07
JP2001017191A (ja) 2001-01-23
KR950011618A (ko) 1995-05-15
TW302369B (enExample) 1997-04-11

Similar Documents

Publication Publication Date Title
DE3888379T2 (de) Leukämie hemmender Faktor.
DE69433666T2 (de) ENTZÜNDUNGSPROTEINE AUS MAKROPHAGEN MIP-3, MIP-4 UND MIP-1Gamma
DE69014162T2 (de) Morphogenetisches Knochenprotein.
DE69635899T2 (de) Polypeptid, das die differenzierung unterdrueckt
DE69633617T3 (de) Il-17 receptor
US5756084A (en) Human stromal derived factor 1α and 1β
DE69736712T2 (de) Verfahren zur milderung von neuropatischen schmerz mit prosaposin verwandten peptiden
DE69630710T2 (de) Humaner tumornekrosefaktor delta und epsilon
DE69017753T2 (de) Tumor-Nekrosefaktor-Bindungsprotein II, seine Reinigung und spezifische Antikörper.
EP0538300B1 (de) O-glycosyliertes ifn-alpha
DE69433648T2 (de) Menschliche chemokin-polypeptide
DE69226592T2 (de) Neue neutrophilaktivierende Faktoren
DE3751677T2 (de) Neue familie von primat-hämatopoietischen wachstumsfaktoren
DE69314754T2 (de) Vorläufer B-Zelle stimulierender Faktor
DE69027031T2 (de) Nicht glycosierte proteine, analoge des menschlichen interleukin-3
EP0456200A1 (de) Muteine des Granulozyten-Kolonie-stimulierenden Faktors (G-CSF)
DE69934239T2 (de) Ly6h-gen
DE69736109T2 (de) Differenzierungsinhibitor
DE68920931T2 (de) Rekombinanter natürlicher Killerzellen-Aktivator.
DE68925199T2 (de) Peptide und polypeptide stammend von den submaxillaren drüsen der ratte, deren entsprechende monoklonale und polyklonale antikörper entsprechende hybridomen und verwendung dieser verbindungen in der diagnose bei bestimmungen und für pharmazeutische zwecke
DE69734141T2 (de) PROTEIN, DAS FÜR MENSCHLICHE Th2-ZELLEN SPEZIFISCH IST, DAFÜR KODIERENDES GEN UND KORRESPONDIERENDE TRANSFORMANTE, REKOMBINANTER VEKTOR UND MONOKLONALER ANTKÖRPER
DE69131421T3 (de) Für den rezeptor des granulozytenkolonie stimulierenden faktors kodierende dns
DE69426076T3 (de) Gereinigte flt3-liganden von saeugentieren, agonisten und antagonisten davon
DE69532874T2 (de) RPDL Protein und kodierende DNS
DE60103078T2 (de) Chemokin mutanten zur behandlung multipler sklerose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition